HC Wainwright Predicts CervoMed’s Q3 Earnings (NASDAQ:CRVO)

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of CervoMed in a report issued on Monday, September 8th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.66) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $11.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.60) EPS, Q1 2026 earnings at ($0.73) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.53) EPS.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.13). The firm had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.45 million. CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.

CRVO has been the subject of several other research reports. Canaccord Genuity Group raised their target price on CervoMed from $21.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Roth Capital restated a “buy” rating and issued a $16.00 target price (down previously from $20.00) on shares of CervoMed in a research note on Tuesday, August 12th. D. Boral Capital raised their target price on CervoMed from $15.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, August 18th. Finally, Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of CervoMed in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.29.

CervoMed Stock Down 3.4%

Shares of NASDAQ CRVO opened at $9.20 on Thursday. CervoMed has a 52 week low of $1.80 and a 52 week high of $20.63. The business has a 50-day simple moving average of $8.82 and a two-hundred day simple moving average of $8.13. The company has a market cap of $85.10 million, a P/E ratio of -3.52 and a beta of -0.72.

Institutional Trading of CervoMed

A number of large investors have recently modified their holdings of CRVO. BNP Paribas Financial Markets purchased a new position in shares of CervoMed during the 4th quarter valued at about $32,000. Rhumbline Advisers increased its stake in CervoMed by 35.5% in the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the period. Marshall Wace LLP purchased a new position in CervoMed in the 2nd quarter worth approximately $76,000. Thompson Davis & CO. Inc. purchased a new position in CervoMed in the 2nd quarter worth approximately $88,000. Finally, Nuveen Asset Management LLC increased its stake in shares of CervoMed by 113.6% during the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after buying an additional 22,104 shares during the period. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.